Genprex, Inc. Files 8-K on Delisting Notice
Ticker: GNPX · Form: 8-K · Filed: Nov 26, 2025 · CIK: 1595248
Sentiment: bearish
Topics: delisting, listing-standards, regulatory
Related Tickers: GNPX
TL;DR
Genprex 8-K: Delisting notice filed. Uh oh.
AI Summary
Genprex, Inc. filed an 8-K on November 26, 2025, to report a notice of delisting or failure to satisfy a continued listing rule or standard, and also filed financial statements and exhibits. The company is incorporated in Delaware and its principal executive offices are located in Austin, Texas.
Why It Matters
This filing indicates potential issues with Genprex, Inc.'s continued listing on an exchange, which could impact its stock trading and investor confidence.
Risk Assessment
Risk Level: high — A notice of delisting or failure to meet listing standards suggests significant financial or operational distress for the company.
Key Players & Entities
- Genprex, Inc. (company) — Registrant
- November 26, 2025 (date) — Filing Date
- Austin, Texas (location) — Principal Executive Offices
- Delaware (location) — State of Incorporation
FAQ
What specific listing rule or standard has Genprex, Inc. failed to satisfy?
The filing does not specify the exact rule or standard that Genprex, Inc. has failed to satisfy, only that a notice has been issued.
What is the date of the earliest event reported in this 8-K filing?
The date of the earliest event reported is November 25, 2025.
What is Genprex, Inc.'s SIC code?
Genprex, Inc.'s Standard Industrial Classification (SIC) code is 2834, Pharmaceutical Preparations.
What is the company's telephone number?
The company's telephone number is (512) 537-7997.
What is the filing date of this 8-K report?
This 8-K report was filed on November 26, 2025.
Filing Stats: 1,155 words · 5 min read · ~4 pages · Grade level 16.8 · Accepted 2025-11-26 08:01:07
Key Financial Figures
- $0.001 — h registered Common Stock , par value $0.001 per share GNPX The Nasdaq Capital Ma
- $1.00 M — tion to demonstrate compliance with the $1.00 Minimum Bid Price requirement set forth i
Filing Documents
- gnpx20251105_8k.htm (8-K) — 33KB
- 0001437749-25-036380.txt ( ) — 161KB
- gnpx-20251125.xsd (EX-101.SCH) — 3KB
- gnpx-20251125_def.xml (EX-101.DEF) — 11KB
- gnpx-20251125_lab.xml (EX-101.LAB) — 15KB
- gnpx-20251125_pre.xml (EX-101.PRE) — 11KB
- gnpx20251105_8k_htm.xml (XML) — 3KB
01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard Transfer of Listing
Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard Transfer of Listing . As previously disclosed, the Nasdaq Hearings Panel (the "Panel") of the Nasdaq Stock Market, LLC ("Nasdaq") had previously notified the Company on October 13, 2025 that the Panel had granted the Company's request for an exception to demonstrate compliance with the $1.00 Minimum Bid Price requirement set forth in Nasdaq Listing Rule 5550(a)(2) (the "Bid Price Requirement") and the minimum stockholders' equity requirement for continued listing on the Nasdaq Capital Market, under Nasdaq Listing Rule 5550(b)(1) (the "Stockholders' Equity Requirement") for continued listing through October 31, 2025. On November 25, 2025, the Company was formally notified that (i) the Panel determined that the Company has regained compliance with the Bid Price Requirement; and (ii) the Panel has also approved the Company's request for an exception until December 31, 2025 to demonstrate long-term compliance with the Stockholders' Equity Requirement (as extended, the "Exception"). As previously disclosed, upon request by the Company, the Panel has discretion to grant the Company continued listing through February 9, 2026. Pursuant to the Exception, the Company is required to, and fully intends to, provide the Panel with prompt notification of any significant events that occur, including any event that may call into question the Company's ability to satisfy the terms of the Exception. If such events do occur, the Company may request a further extension beyond December 31, 2025 to regain compliance with the Stockholders' Equity Requirement. The Panel has reserved the right to reconsider the terms of the Exception based on any event, condition or circumstance that exists or develops that would, in the Panel's opinion, make continued listing of the Company's securities on Nasdaq inadvisable or unwarranted. There can be no assurance that the Panel would exercise their discretion to
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. GENPREX, INC. Date: November 26, 2025 By: /s/ Ryan Confer Ryan Confer President, Chief Executive Officer and Chief Financial Officer (Principal Executive Officer and Principal Financial and Accounting Officer)